|

UPLYFT For Lymphoma Survivors

RECRUITINGN/ASponsored by Dana-Farber Cancer Institute
Actively Recruiting
PhaseN/A
SponsorDana-Farber Cancer Institute
Started2022-02-08
Est. completion2026-05-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Lymphoma Survivors Phase 1 and 2:

* Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
* Age ≥ 18 years
* Interval of 3 months to 24 months from completion of first-line treatment
* In complete remission after first line of treatment
* Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
* Access to computer (for videoconferencing)

Lymphoma clinicians and mental health clinicians Phase 1:

* Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
* Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians

Exclusion Criteria:

Lymphoma Survivors Phase 1:

* Age \< 18 years
* Concurrent other malignancy
* Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).

Lymphoma Survivors Phase 2:

* Age \< 18 years
* Concurrent other malignancy
* Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).

  * Our study will exclude members of the following special populations:

    * Adults unable to consent
    * Individuals who are not yet adults (infants, children, teenagers)
    * Pregnant women
    * Prisoners

Conditions3

CancerLymphomaSurvivorship

Locations1 site

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Oreofe O Odejide, MD, MPH617-632-6864Oreofe_Odejide@dfci.harvard.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.